Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21829027 | 0.73 | MAPT (1.00) | MAPTALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL29959525 | 0.73 | MAPT (1.00) | MAPTALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL9016652 | 0.67 | SMN1; SMN2 (0.51) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL1614544 | 0.67 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL3626830 | 0.67 | SIGMAR1 (0.67) | MAPTSIGMAR1ALDH1A1RAB9AKDM4E | |
| SCHEMBL29666490 | 0.67 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL11856611 | 0.67 | MAPT (0.55) | MAPTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL18773992 | 0.66 | SIGMAR1 (0.53) | SIGMAR1RAB9AHPGDMEN1KMT2A | |
| SCHEMBL27616524 | 0.66 | SIGMAR1 (0.53) | SIGMAR1RAB9AMEN1KMT2A | |
| SCHEMBL26620285 | 0.66 | SIGMAR1 (0.61) | SIGMAR1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020072492-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | BARUCH S. BLUMBERG INSTITUTE (US) | 2020-04-09 | — | — | WO | claimed |
| US-20210347752-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | BARUCH S. BLUMBERG INSTITUTE | 2021-11-11 | — | — | US | disclosed |
| WO-2020072492-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | BARUCH S. BLUMBERG INSTITUTE (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347752-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | STING1, CGAS, MAVS | MAPT 4381/4885SIGMAR1 4088/4885ALDH1A1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.